Pioneering the development
of engineered IgM antibodies
NEWS
PRESENTATIONS & PUBLICATIONS
Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants
Published in Nature, 03 June 2021 Citation: Ku, Z., Xie, X., Hinton, P.R. et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature (2021)…
Pharmacodynamic Assessment of an IgM Antibody Using BRGSF-HIS Mice
Predict Innovation — May 20, 2021
Next-Generation Approaches to COVID-19 Therapeutics: Clinical Challenges and Engineering Solutions
PEGS Boston – May 11-13, 2021 Session: Novel and Alternative Approaches to Developing Covid-19 Therapeutics – May 11, 2021
Engineering the Future: Next Gen Platforms in Oncology
Cancer Progress Virtual – May 4-6, 2021 Keynote Address – May 4, 2021
Multimeric IgM Antibodies Targeting DR5 are Potent and Rapid Inducers of Tumor Cell Apoptosis In Vitro and In Vivo
Triple Negative Breast Cancer Drug Development Digital Summit – April 28-29, 2021 Session: Uncovering the Latest Targeted Therapy Approaches – April 29, 2021
Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity
AACR Annual Meeting 2021 Virtual – April 10-15, 2021 Session: Therapeutic Mechanisms of Novel Anticancer Agent, Abstract No. 52
Clinical Challenges and Engineering Solutions in Cancer Immunotherapy: What Do We Need Now?
Nature Research Webcast: Immuno-oncology: IgG and Beyond – April 6, 2021
Potent Anti-Tumor Activity of IGM-8444, an Agonist DR5 IgM, Displays Strong Synergy with Chemotherapy and Inducers of Apoptosis
Festival of Biologics USA – March 29 to April 1, 2021
Delivery of IL-15 to PD-L1 Expressing Tumors with an Anti-PD-L1 IgM
Cytokine-Based Cancer Immunotherapies Summit – March 24-25, 2021
In the Media: Nature Biotechnology – Bispecific Antibodies Poised to Deliver Wave of Cancer Therapies
Citation: Sheridan, C. Bispecific antibodies poised to deliver wave of cancer therapies. Nat Biotechnol 39, 251–254 (2021) https://doi.org/10.1038/s41587-021-00850-6